LACTOLOGY FOUNDATION

A09A Digestives, Including Enzymes: Toxicological and Lactation Monograph

ATC Class and General Pharmacology

ATC class A09A belongs to the anatomical main group A – Alimentary Tract and Metabolism and the therapeutic subgroup A09 – Digestives, Including Enzymes. It covers medicinal products intended to support digestion, including enzyme preparations, acid preparations, and combinations of digestive enzymes with acidifying agents. The ATC system distinguishes these medicines from enzymes used for other therapeutic purposes, such as systemic enzyme therapy, wound-related proteolysis, or inflammatory conditions.atcddd.fhi

At the subgroup level, A09A includes:

• Enzyme preparations used in digestive disorders, including single enzymes and combinations with lipolytic, proteolytic, and amylolytic activity.
• Acid preparations intended to modify gastric acidity or support digestion in selected clinical contexts.
• Enzyme–acid combinations, in which enzymatic activity is combined with an acidifying component.

The principal pharmacological purpose of this class is local action within the gastrointestinal lumen. Digestive enzyme preparations facilitate the hydrolysis of dietary macronutrients:

• Lipolytic activity promotes digestion of triglycerides into absorbable fatty acids and monoglycerides.
• Proteolytic activity supports the degradation of dietary proteins into peptides and amino acids.
• Amylolytic activity assists carbohydrate digestion.
• Other specialized enzymes may assist digestion of particular substrates, such as lactose or selected complex carbohydrates.

The intended clinical role is therefore compensatory or supportive rather than systemically pharmacodynamic. In many formulations, especially those designed for pancreatic enzyme replacement, pharmaceutical strategies such as enteric coating are used to protect enzymes from gastric acid and enable activity in the duodenum or proximal small intestine. Acid-containing A09A preparations may instead seek to supplement or modify the chemical conditions relevant to gastric digestion.

This class is pharmacologically heterogeneous. Consequently, A09A should not be treated as a uniform group with identical indications, potency, formulation characteristics, systemic exposure, or lactation evidence. The safety assessment of an individual product must account for its exact active ingredients, source material, dosage, formulation, excipients, and therapeutic indication.

Toxicological Profile

The general toxicological profile of A09A medicines is dominated by their predominantly local gastrointestinal activity and, for many enzyme preparations, limited intact systemic absorption. Digestive enzymes are generally proteins or protein-derived biological preparations that act in the gastrointestinal tract. After oral administration, they may be degraded by digestive processes, inactivated by pH conditions, or act locally before being eliminated. Therefore, systemic toxicological effects are usually not the primary concern when these medicines are used at conventional therapeutic doses.

The principal adverse effects associated with digestive preparations are commonly gastrointestinal and may include:

• Abdominal discomfort, nausea, altered bowel habit, diarrhoea, constipation, abdominal cramping, or bloating.
• Local gastrointestinal irritation, particularly with preparations containing acidifying agents or when administration is inappropriate.
• Hypersensitivity reactions in susceptible persons, especially where products are derived from animal, microbial, fungal, or other biological sources.
• Product-specific risks related to dose, formulation, coexisting gastrointestinal disease, or concomitant medicines.

High-dose or prolonged administration of some digestive enzyme products may require additional caution. This is particularly relevant for concentrated replacement preparations, where adverse effects may be dose-related and where underlying pancreatic, gastrointestinal, metabolic, or nutritional disease can independently contribute to symptoms or complications. Such risks must be assessed at the individual-product level rather than extrapolated indiscriminately across all A09A products.

Acid-containing products warrant separate toxicological consideration. Their potential harms depend on acid strength, concentration, volume, dosage form, dilution requirements, and the patient’s gastrointestinal status. They may aggravate mucosal irritation or symptoms in individuals with active peptic disease, erosive gastrointestinal conditions, severe reflux symptoms, or impaired mucosal integrity. Improper administration can increase the risk of local irritation to the mouth, oesophagus, or stomach.

For enzyme products of biological origin, allergy history is clinically relevant. Hypersensitivity may arise from the active material itself, source-derived proteins, or formulation excipients. Patients with known relevant food, animal-derived, fungal, or pharmaceutical excipient allergies should receive product-specific review before treatment.

An additional toxicological issue concerns non-prescription dietary supplements marketed as “digestive enzymes.” These products may not have the same manufacturing standards, evidence base, ingredient consistency, dosing reliability, or post-marketing pharmacovigilance as licensed medicinal products. A lactating patient should not assume that a commercial supplement is interchangeable with a prescribed or regulated digestive medicine merely because both are described as enzyme products.

Lactation Pharmacology and Infant Exposure

The expected transfer of many conventional digestive enzyme preparations into human milk is low because their pharmacological action is largely intraluminal and intact maternal systemic absorption is generally limited. Even if a small amount of proteinaceous enzyme material were to reach milk, oral exposure of the infant would ordinarily be subject to digestion within the infant gastrointestinal tract. These considerations provide a biologically plausible basis for low infant exposure from many enzyme-based A09A medicines.

However, low expected exposure does not mean that direct clinical lactation data are available for every product in the class. Evidence is often sparse, particularly for older products, multi-ingredient preparations, acid–enzyme combinations, and non-prescription supplements. Consequently, a class-level assessment should be regarded as a pharmacological framework rather than a substitute for evaluation of the individual active substance.

Available lactation evidence for pancrelipase, a representative pancreatic enzyme preparation, indicates that expert opinion considers it acceptable during breastfeeding. LactMed also reports its use in mothers of breastfed infants in a clinical context involving maternal dietary protein exposure, although this observation should not be interpreted as evidence that all digestive enzymes, all formulations, or all indications have equivalent lactation data.ncbi.nlm.nih+1

Important determinants of potential infant exposure include:

• Maternal systemic bioavailability of the specific active substance.
• Molecular size and protein nature of the enzyme or other active component.
• Dose and pharmaceutical formulation, including delayed-release or enteric-coated products.
• Presence of co-formulated acidifying agents or other pharmacologically active substances.
• Maternal gastrointestinal disease, which may affect product selection and dosing but does not necessarily increase milk transfer.
• Infant age, prematurity, clinical fragility, gastrointestinal disease, allergy history, and capacity to tolerate dietary or medicinal exposures.

For standard enzyme preparations used as indicated, clinically meaningful concentrations in milk are not generally expected. The more relevant concern is often indirect: whether maternal treatment is appropriate, whether the product contains additional ingredients, whether it is a regulated medicine or a variable-composition supplement, and whether the underlying maternal condition requires more comprehensive management.

Lactological Safety Assessment and Clinical Recommendations

As a broad class, standard orally administered digestive enzyme preparations in A09A can generally be considered compatible with breastfeeding when clinically indicated, particularly when they act locally in the maternal gastrointestinal tract and have negligible systemic bioavailability. This conclusion is strongest for well-characterized, regulated single-agent or conventional replacement enzyme preparations and should be applied more cautiously to mixed products, acid-containing preparations, and unregulated dietary supplements.

Breastfeeding should not be routinely interrupted solely because a mother requires a conventional digestive enzyme product. For mothers who require ongoing treatment for a clinically important digestive or pancreatic condition, maintaining effective maternal therapy is often preferable to discontinuation, undertreatment, malabsorption, weight loss, nutritional deterioration, or deterioration of the underlying disease. In pancreatic insufficiency or other conditions associated with impaired digestion, adequate maternal nutritional management is itself relevant to lactation health and maternal wellbeing.

Clinical approach

• Prefer a licensed, single-purpose medicinal product with a clearly stated composition whenever possible.
• Use the lowest effective dose that adequately treats the maternal condition, while recognizing that replacement therapy may require individualized dose titration.
• Avoid substituting prescribed products with unverified “digestive enzyme” supplements, particularly if ingredient sources, enzyme activity, contaminants, herbal additives, or dosing are uncertain.
• Review acid-containing preparations individually, especially in mothers with ulcer disease, severe reflux, oesophagitis, gastrointestinal bleeding, or significant mucosal disease.
• Consider allergy history when selecting preparations derived from animal, microbial, or fungal sources.
• Review co-administered ingredients carefully in combination products; lactation compatibility must be based on the entire formulation, not on the enzyme component alone.
• Seek product-specific lactation advice for premature or medically fragile infants, infants with severe gastrointestinal disease, infants with known relevant allergies, or situations involving unusually high maternal doses.

Infant monitoring

Routine special monitoring is usually unnecessary when a standard digestive enzyme preparation is used appropriately in a healthy, full-term breastfed infant. Nevertheless, caregivers should seek clinical advice if the infant develops persistent vomiting, diarrhoea, rash, wheeze, feeding difficulty, poor weight gain, unusual irritability, or other symptoms temporally associated with maternal treatment. Such events are expected to be uncommon and should prompt assessment of both maternal medication exposure and alternative clinical causes.

Overall conclusion

A09A digestive medicines are a diverse class, but most conventional oral enzyme preparations have pharmacological characteristics that predict minimal transfer into breast milk and low risk of clinically significant infant exposure. The available lactation assessment for pancrelipase supports compatibility with breastfeeding, while evidence for other members of the class may be limited and should not be overgeneralized.ncbi.nlm.nih

The most appropriate lactological strategy is to preserve necessary maternal treatment, select a regulated and well-characterized product, avoid unnecessary multi-ingredient or poorly standardized supplements, and perform individual review when acid-containing products, high-dose regimens, unusual formulations, or vulnerable infants are involved.